Nikoral Mint: Nicotine Sublingual Tablets for Smoking Cessation
Nicotine replacement therapy (NRT) sublingual tablet with mint flavor to help you quit smoking
Nikoral Mint is a nicotine replacement therapy (NRT) product available as sublingual tablets with a mint flavor. It is used to help adults quit smoking by delivering controlled doses of nicotine through the lining of the mouth, reducing withdrawal symptoms and cravings. Nikoral Mint is available over the counter in 2 mg and 4 mg strengths and is part of a comprehensive approach to tobacco cessation that may include behavioral support and counseling.
Quick Facts
Key Takeaways
- Nikoral Mint is a sublingual nicotine tablet that dissolves under the tongue to help smokers quit by reducing withdrawal symptoms and cravings.
- Available in 2 mg (for lighter smokers) and 4 mg (for heavier smokers) strengths without a prescription in most countries.
- The recommended treatment course is approximately 12 weeks, with a gradual dose reduction schedule to wean off nicotine dependence.
- Nicotine replacement therapy has been shown in Cochrane systematic reviews to increase quit rates by 50-70% compared to placebo.
- Common side effects are generally mild and include mouth irritation, hiccups, nausea, and throat discomfort, most of which diminish with continued use.
What Is Nikoral Mint and What Is It Used For?
Nikoral Mint belongs to the class of medications known as nicotine replacement therapies (NRTs). These are pharmacological aids that provide the body with nicotine in a safer, controlled form without the thousands of harmful chemicals produced by burning tobacco. The sublingual tablet format means the tablet is placed under the tongue where it dissolves, allowing nicotine to be absorbed directly through the oral mucosa into the bloodstream.
Tobacco dependence is recognized by the World Health Organization (WHO) as a chronic relapsing condition that causes more than 8 million deaths globally each year. Nicotine, the primary addictive substance in tobacco, creates physical dependence by binding to nicotinic acetylcholine receptors in the brain, triggering dopamine release and creating a cycle of reward and withdrawal. When a smoker attempts to quit, the sudden absence of nicotine leads to withdrawal symptoms including intense cravings, irritability, anxiety, difficulty concentrating, increased appetite, and depressed mood.
Nikoral Mint addresses this challenge by providing a measured dose of pharmaceutical-grade nicotine that satisfies the body's physical dependence while the individual works on breaking the behavioral and psychological habits associated with smoking. The nicotine in Nikoral Mint is formulated as a beta-cyclodextrin complex, which provides stable, predictable release characteristics and a pleasant mint taste that improves compliance.
According to the Cochrane Database of Systematic Reviews, all forms of NRT (including sublingual tablets, patches, gum, lozenges, and inhalers) increase the likelihood of successfully quitting smoking by approximately 50-70% compared to placebo or no treatment. When NRT is combined with behavioral support and counseling, success rates improve further. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) both recognize NRT as a first-line pharmacotherapy for smoking cessation.
Nikoral Mint may be used as a standalone quit-smoking aid or in combination with other NRT products. Some evidence-based guidelines recommend combining a long-acting NRT (such as a nicotine patch) with a short-acting product (such as sublingual tablets) for smokers with high nicotine dependence, as this combination approach has been shown to be more effective than using a single NRT product alone.
What Should You Know Before Taking Nikoral Mint?
Contraindications
Nikoral Mint should not be used by individuals who are hypersensitive to nicotine or any of the excipients in the formulation. Non-smokers and occasional smokers (those not physically dependent on nicotine) should not use this product, as nicotine can cause adverse effects including nausea, dizziness, and headache in nicotine-naive individuals.
Children under 12 years of age should not use nicotine replacement products unless specifically directed by a physician. The nicotine doses in these products are calibrated for adult smokers with established nicotine tolerance, and even small amounts of nicotine can be toxic to young children. All nicotine products must be stored securely out of reach of children.
Warnings and Precautions
Certain medical conditions require careful consideration and potentially medical supervision when using Nikoral Mint. Patients with the following conditions should consult their healthcare provider before initiating NRT:
- Cardiovascular disease: Including recent myocardial infarction (within the past 4 weeks), unstable angina, severe cardiac arrhythmias, or recent stroke. While NRT is generally considered safer than continuing to smoke for most cardiac patients, medical supervision is recommended.
- Uncontrolled hypertension: Nicotine can temporarily raise blood pressure. Patients with poorly controlled hypertension should be monitored.
- Diabetes mellitus: Smoking cessation (with or without NRT) can affect insulin sensitivity. Diabetic patients may need to adjust their medication doses during and after quitting.
- Severe hepatic impairment: Nicotine is metabolized primarily in the liver. Patients with severe liver disease may experience higher plasma nicotine levels.
- Severe renal impairment: Nicotine and its metabolites are excreted by the kidneys. Dose adjustments may be necessary for patients with significant kidney disease.
- Active peptic ulcer disease: Nicotine may exacerbate symptoms. Use with caution and medical supervision.
- Pheochromocytoma: Nicotine can stimulate catecholamine release from adrenal tumors.
- Hyperthyroidism: Nicotine may worsen symptoms in patients with uncontrolled thyroid overactivity.
If you experience chest pain, irregular heartbeat, or signs of nicotine overdose (severe nausea, vomiting, dizziness, weakness, rapid heartbeat) while using Nikoral Mint, stop using the product and seek medical attention immediately. Nicotine overdose can occur if you use too many tablets or continue smoking while using NRT.
Pregnancy and Breastfeeding
Smoking during pregnancy is associated with numerous serious risks including premature birth, low birth weight, placental complications, and sudden infant death syndrome (SIDS). Quitting smoking is one of the most important steps a pregnant woman can take to protect her health and the health of her baby.
However, nicotine itself (regardless of the delivery method) can harm fetal development by reducing blood flow to the placenta, affecting fetal heart rate, and potentially impacting brain development. For this reason, pregnant women should first attempt to quit smoking using non-pharmacological methods such as behavioral counseling, support groups, and cognitive behavioral therapy.
If non-pharmacological approaches are insufficient, healthcare providers may consider NRT as a potential option, as it eliminates exposure to carbon monoxide, tar, and the thousands of other toxic substances in cigarette smoke. The intermittent-dose forms (such as sublingual tablets, gum, or lozenges) may be preferred over the nicotine patch during pregnancy, as they deliver lower total daily nicotine exposure. Any use of NRT during pregnancy should be under direct medical supervision.
Nicotine passes into breast milk and can affect the nursing infant. If NRT is used during breastfeeding, the intermittent-dose products should be used immediately after nursing rather than before, to minimize the infant's nicotine exposure. Consult your healthcare provider for personalized advice.
How Does Nikoral Mint Interact with Other Drugs?
It is important to understand that many drug interactions attributed to nicotine replacement therapy are actually caused by smoking cessation itself. Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs) that are potent inducers of hepatic cytochrome P450 enzymes, particularly CYP1A2. When a person stops smoking, the activity of these enzymes decreases, potentially leading to higher plasma concentrations of medications metabolized by these pathways. This effect occurs regardless of whether NRT is used.
Major Interactions
The following medications may require dose adjustments when you quit smoking. Discuss these with your healthcare provider:
| Medication | Effect of Quitting | Action Required |
|---|---|---|
| Theophylline | Plasma levels may increase by up to 100% due to reduced CYP1A2 activity | Monitor levels closely; dose reduction likely needed |
| Warfarin | Increased anticoagulant effect; INR may rise | Monitor INR frequently; adjust dose as needed |
| Insulin | Increased insulin sensitivity after cessation | Monitor blood glucose; dose reduction may be necessary |
| Clozapine | Plasma levels may increase significantly via CYP1A2 | Mandatory dose reduction; monitor closely for toxicity |
| Olanzapine | Plasma levels may increase via CYP1A2 | Consider dose reduction; monitor for sedation |
Minor Interactions
Some additional medications may have minor interactions related to smoking cessation. These typically do not require immediate action but should be discussed with your healthcare provider:
| Medication | Effect of Quitting | Clinical Significance |
|---|---|---|
| Caffeine | Increased plasma levels after cessation | May cause jitteriness; reduce coffee intake |
| Benzodiazepines | Slightly increased sedative effect | Monitor for increased drowsiness |
| Beta-blockers | Mild increase in plasma concentration | Monitor blood pressure and heart rate |
| Fluvoxamine | CYP1A2 substrate; levels may increase | Monitor for increased side effects |
Always inform your doctor and pharmacist about all medications you are taking before starting Nikoral Mint or any smoking cessation program. This includes prescription medications, over-the-counter drugs, and herbal supplements. A comprehensive medication review can help identify potential interactions and plan appropriate dose adjustments.
What Is the Correct Dosage of Nikoral Mint?
Adults
The recommended dose is individualized based on the degree of nicotine dependence. A common method to assess dependence is the Fagerström Test for Nicotine Dependence, though a simplified approach uses the number of cigarettes smoked per day and time to first cigarette after waking.
2 mg Strength (Low to Moderate Dependence)
Recommended for smokers who smoke fewer than 20 cigarettes per day or who smoke their first cigarette more than 30 minutes after waking. Typical dosage: 1 tablet placed under the tongue every 1-2 hours as needed. Maximum 30 tablets per day.
4 mg Strength (High Dependence)
Recommended for smokers who smoke 20 or more cigarettes per day or who smoke their first cigarette within 30 minutes of waking. Typical dosage: 1 tablet placed under the tongue every 1-2 hours as needed. Maximum 30 tablets per day.
| Treatment Phase | Duration | Dosage |
|---|---|---|
| Phase 1: Full Dose | Weeks 1-6 | 1 tablet every 1-2 hours (typically 8-12 tablets/day) |
| Phase 2: Gradual Reduction | Weeks 7-9 | Reduce number of tablets by approximately half |
| Phase 3: Final Tapering | Weeks 10-12 | Continue reducing until 1-2 tablets per day, then stop |
How to use: Place one tablet under the tongue and allow it to dissolve completely. Do not chew, crush, or swallow the tablet whole. Avoid eating or drinking while the tablet is dissolving, as this may reduce absorption. The tablet typically dissolves within 20-30 minutes. If you experience a strong craving between regular doses, an additional tablet may be used, but do not exceed the maximum daily dose.
Children and Adolescents
Nikoral Mint is not recommended for individuals under 18 years of age without specific medical advice. Adolescent smokers (ages 12-17) who are nicotine dependent may benefit from NRT under the supervision of a healthcare provider, but over-the-counter use is not recommended for this age group. The safety and efficacy of NRT in children under 12 have not been established.
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have cardiovascular disease, renal impairment, or hepatic impairment, which may necessitate closer monitoring or medical supervision. Elderly patients should consult their healthcare provider before starting NRT, particularly if they have any concurrent medical conditions or take multiple medications.
Missed Dose
Unlike many medications with fixed dosing schedules, Nikoral Mint is used on an as-needed basis for craving control. There is no strict "missed dose" concern. If you forget to use a tablet at your usual interval, simply use one when you next feel a craving or at your next scheduled time. Do not use extra tablets to compensate for a missed dose. Maintaining a regular schedule during the initial treatment phase helps maintain consistent nicotine levels and reduces breakthrough cravings.
Overdose
Nicotine overdose can occur if too many tablets are used in a short period or if NRT is used simultaneously with continued heavy smoking. The minimum lethal dose of nicotine in adults is estimated at approximately 40-60 mg, though individual tolerance varies significantly among established smokers.
Seek immediate medical attention if you or someone else experiences: severe nausea and vomiting, excessive salivation, abdominal pain, diarrhea, cold sweats, headache, dizziness, hearing and visual disturbances, tremor, confusion, weakness, or rapid or irregular heartbeat. In severe cases, collapse, convulsions, and respiratory failure can occur. Contact your local poison control center or emergency services immediately.
Treatment of nicotine overdose is primarily supportive. Activated charcoal may be administered if the ingestion was recent. There is no specific antidote for nicotine poisoning. The relatively short half-life of nicotine (approximately 2 hours) means that symptoms typically resolve as the nicotine is eliminated from the body, provided no further exposure occurs.
What Are the Side Effects of Nikoral Mint?
Like all nicotine replacement products, Nikoral Mint can cause side effects, although not everyone experiences them. Many of the side effects observed during NRT use are also symptoms of nicotine withdrawal itself, making it sometimes difficult to distinguish between the two. Most side effects are mild to moderate in severity and tend to diminish within the first two weeks of use as the body adapts.
The side effects are categorized below according to their frequency of occurrence, based on clinical trial data and post-marketing surveillance reports submitted to regulatory agencies including the EMA and FDA:
Very Common
Affects more than 1 in 10 users
- Mouth and throat irritation or tingling
- Hiccups
- Nausea (especially during the first few days)
- Increased salivation
- Burning sensation under the tongue
Common
Affects 1 in 10 to 1 in 100 users
- Headache
- Dizziness
- Gastrointestinal discomfort (indigestion, flatulence)
- Dry mouth or increased thirst
- Jaw muscle ache (from sublingual placement)
- Coughing
- Sore throat
- Altered taste perception
Uncommon
Affects 1 in 100 to 1 in 1,000 users
- Palpitations or increased heart rate
- Flushing
- Oral ulceration or mouth sores
- Chest discomfort
- Insomnia or vivid dreams
- Muscle pain
- Numbness or tingling in extremities
Rare
Affects fewer than 1 in 1,000 users
- Allergic reactions (rash, urticaria, angioedema)
- Cardiac arrhythmias
- Severe dysphagia (difficulty swallowing)
- Reversible atrial fibrillation
- Anaphylaxis (extremely rare)
It is important to distinguish between side effects of Nikoral Mint and symptoms of nicotine withdrawal, which can occur even when using NRT if the nicotine dose is lower than what the body was accustomed to from smoking. Common withdrawal symptoms include irritability, anxiety, restlessness, difficulty concentrating, increased appetite, weight gain, and depressed mood. These withdrawal symptoms are a normal part of the quitting process and are not caused by the NRT product itself.
Contact your healthcare provider if side effects are severe, persistent, or worsening. Seek immediate medical attention if you experience signs of a serious allergic reaction (difficulty breathing, swelling of face or throat), chest pain, or severe palpitations. Report any unexpected side effects to your healthcare provider or to your national pharmacovigilance center.
How Should You Store Nikoral Mint?
Proper storage of Nikoral Mint ensures the product maintains its efficacy and safety throughout its shelf life. Follow these storage guidelines carefully:
- Temperature: Store at room temperature, below 25°C (77°F). Do not refrigerate or freeze. Avoid storing in locations that may experience temperature extremes, such as in a car during summer or near heating sources.
- Moisture: Keep the tablets in their original blister packaging until ready to use. The blister pack protects the tablets from humidity, which can affect their dissolution properties and nicotine stability.
- Light: Protect from direct sunlight and strong artificial light, as UV radiation can degrade nicotine over time.
- Child safety: This is critically important. Nicotine is highly toxic to children, and even a single tablet can cause serious poisoning in a small child. Store all nicotine products in a secure location that is inaccessible to children. Used and unused products should be disposed of safely.
- Shelf life: Do not use Nikoral Mint after the expiry date printed on the packaging. The expiry date refers to the last day of the stated month.
Disposal of unused or expired tablets should follow local pharmaceutical waste guidelines. Do not flush nicotine products down the toilet or throw them in household trash where children or pets could access them. Many pharmacies offer take-back programs for safe medication disposal. If no take-back program is available, fold used blister packs with any remaining tablets inside and place them in a sealed container before disposing of in the household waste.
What Does Nikoral Mint Contain?
Understanding the composition of Nikoral Mint is important, particularly for individuals with known allergies or sensitivities to specific ingredients.
Active Ingredient
The active substance is nicotine, provided as a nicotine beta-cyclodextrin complex. Beta-cyclodextrin is a natural cyclic oligosaccharide that encapsulates the nicotine molecule, improving its stability, controlling its release during dissolution, and masking the bitter taste of nicotine. Each tablet contains either 2 mg or 4 mg of nicotine (measured as the free base equivalent).
Inactive Ingredients (Excipients)
The inactive ingredients serve various pharmaceutical purposes including tablet formation, flavor, and stability:
- Mannitol: A sugar alcohol used as a tablet filler and sweetener. It provides the bulk of the tablet and a slightly sweet taste. Mannitol is generally well tolerated and does not significantly affect blood sugar levels.
- Beta-cyclodextrin: The complexing agent that encapsulates nicotine for controlled release and taste masking.
- Crospovidone: A disintegrant that helps the tablet break apart quickly under the tongue for rapid nicotine release.
- Magnesium stearate: A lubricant used in tablet manufacturing to prevent the tablet from sticking to the production equipment.
- Colloidal silicon dioxide: A flow agent used in tablet manufacturing to improve the uniformity of the tablet blend.
- Mint flavoring: Provides the characteristic mint taste that helps mask the natural bitterness of nicotine and improves user acceptance and compliance.
- Aspartame (in some formulations): An artificial sweetener. Individuals with phenylketonuria (PKU) should be aware that aspartame is a source of phenylalanine. Check the specific product packaging for ingredient details.
If you have known allergies or intolerances to any of the ingredients listed above, consult your pharmacist or healthcare provider before using Nikoral Mint. Always read the full list of ingredients on the product packaging, as formulations may vary between manufacturers and markets.
Frequently Asked Questions About Nikoral Mint
References and Medical Sources
This article is based on the following peer-reviewed sources and authoritative medical guidelines:
- Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews. 2018;5(5):CD000146. doi:10.1002/14651858.CD000146.pub5
- World Health Organization. WHO Report on the Global Tobacco Epidemic 2023. Geneva: WHO; 2023.
- European Medicines Agency. Guideline on the development of medicinal products for the treatment of smoking and nicotine dependence. EMA/CHMP/EWP/271303/2019.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Nicotine Replacement Therapy Products. FDA; 2023.
- Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2019;4(4):CD013308.
- National Institute for Health and Care Excellence (NICE). Tobacco: preventing uptake, promoting quitting and treating dependence. NICE guideline [NG209]. 2021.
- Benowitz NL. Nicotine addiction. New England Journal of Medicine. 2010;362(24):2295-2303. doi:10.1056/NEJMra0809890
- Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database of Systematic Reviews. 2015;(12):CD010078.
- British National Formulary (BNF). Nicotine. NICE Evidence Services. Accessed February 2026.
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence. British Journal of Addiction. 1991;86(9):1119-1127.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed physicians, pharmacists, and clinical pharmacologists with expertise in smoking cessation and nicotine replacement therapy.
iMedic Clinical Pharmacology Team — specialists in drug information and patient education with extensive experience in tobacco cessation pharmacotherapy.
iMedic Medical Review Board — independent panel of board-certified physicians who verify all medical claims against current evidence-based guidelines (WHO, EMA, NICE, FDA).
Editorial Standards: All content follows the iMedic Editorial Standards, using the GRADE evidence framework. No commercial funding or pharmaceutical industry influence. Last medical review: .